Company news

Sanofi SA news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

December 23, 2025

Sanofi: Information concerning the total number of voting rights and shares - November 2025

December 22, 2025

Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation

December 19, 2025

Press release: Availability of the Q4 2025 Aide memoire

December 17, 2025

Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema

December 17, 2025

Market update

December 16, 2025

Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis

December 15, 2025

Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases

December 11, 2025

InduPro Therapeutics Announces Strategic Investment from Sanofi and a Research Collaboration to Advance a Novel Bispecific for Autoimmune Disorders

December 10, 2025

Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 2025 ASH Annual Meeting

December 5, 2025

Press Release: Sanofi completes acquisition of Vicebio

December 4, 2025

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

November 25, 2025

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

November 25, 2025

Sanofi wins the 2025 Prix Galien Canada innovative product award

November 20, 2025

Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors

November 18, 2025

Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes

November 14, 2025

Sanofi: Information concerning the total number of voting rights and shares – October 2025

November 13, 2025

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

November 7, 2025

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

November 7, 2025

Rezurock® now covered in Quebec for people living with chronic graft-versus-host disease (GVHD)

November 6, 2025

United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb

November 3, 2025

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

October 28, 2025

Press release: Sanofi successfully prices USD 3 billion of bond issue

October 28, 2025

UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

October 27, 2025

Press release: Q3: continued sales and earnings progress

October 24, 2025

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

October 23, 2025

Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer

October 22, 2025

Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

October 22, 2025

Correction: Sanofi-Aventis Canada Inc.

October 21, 2025

Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors

October 20, 2025

Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose

October 20, 2025

Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia

October 17, 2025

Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease

October 17, 2025

Sanofi: Information concerning the total number of voting rights and shares - September 2025

October 14, 2025

BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci’s ASCEND Platform

October 8, 2025

Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors

October 8, 2025

Sanofi: Investițiile în prevenție susțin sănătatea și competitivitatea Europei

May 7, 2025

Sanofi: A megelőzésbe való befektetés Európa egészségének és versenyképességének alapja

May 7, 2025

Sanofi: Investing in prevention builds Europe’s health and competitiveness

May 6, 2025

← Newer news releases

Calls

The 5 newest of 15 calls. Every call is listed under its year.

Decks

The 5 newest of 94 decks. Every deck is listed under its year.